Kiniksa Pharmaceuticals International, plc $KNSA Shares Acquired by Trexquant Investment LP

Key Points

• Trexquant Investment LP has increased its stake in Kiniksa Pharmaceuticals by 192.5%, owning 236,483 shares valued at approximately $5.25 million as of the latest SEC filing.
• Kiniksa Pharmaceuticals reported a quarterly earnings per share (EPS) of $0.23, surpassing analysts' expectations of $0.18, with revenue of $156.80 million for the quarter.
• Various institutional investors, including Deutsche Bank AG and Victory Capital Management, have significantly increased their stakes in Kiniksa, indicating strong institutional interest in the company.

Trexquant Investment LP boosted its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 192.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 236,483 shares of the company's stock after purchasing an additional 155,641 shares during the period. Trexquant Investment LP owned about 0.32% of Kiniksa Pharmaceuticals International worth $5,252,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KNSA. Ieq Capital LLC bought a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $969,000. Corebridge Financial Inc. lifted its holdings in Kiniksa Pharmaceuticals International by 3.6% during the 1st quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after buying an additional 549 shares during the last quarter. Walleye Capital LLC bought a new position in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $1,915,000. Advantage Alpha Capital Partners LP lifted its holdings in Kiniksa Pharmaceuticals International by 52.9% during the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,597 shares of the company's stock worth $302,000 after buying an additional 4,707 shares during the last quarter. Finally, Martingale Asset Management L P lifted its holdings in Kiniksa Pharmaceuticals International by 1.3% during the 1st quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock worth $1,111,000 after buying an additional 640 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Insider Buying and Selling

In other news, CFO Mark Ragosa sold 18,889 shares of the business's stock in a transaction on Monday, August 4th. The stock was sold at an average price of $32.89, for a total value of $621,259.21. Following the sale, the chief financial officer owned 27,009 shares of the company's stock, valued at approximately $888,326.01. The trade was a 41.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John F. Paolini sold 29,325 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the sale, the insider directly owned 57,403 shares in the company, valued at $1,868,467.65. This represents a 33.81% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 558,403 shares of company stock worth $18,078,671. 53.48% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Stock Up 0.6%

Kiniksa Pharmaceuticals International stock traded up $0.20 during mid-day trading on Friday, hitting $35.71. 328,234 shares of the company's stock traded hands, compared to its average volume of 429,216. The firm has a 50 day moving average price of $30.95 and a 200 day moving average price of $26.54. The company has a market cap of $2.65 billion, a PE ratio of 892.97 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $35.84.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. The firm had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 30th. Finally, Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.